🇺🇸 FDA
Patent

US 9745585

RNAi-mediated inhibition of histamine receptor H1-related conditions

granted A61PA61P11/02A61P11/06

Quick answer

US patent 9745585 (RNAi-mediated inhibition of histamine receptor H1-related conditions) held by Arrowhead Pharmaceuticals, Inc. expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Aug 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P11/02, A61P11/06, A61P17/00, A61P27/02